KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Change in Cash (2016 - 2025)

Historic Change in Cash for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to -$21.8 million.

  • Emergent BioSolutions' Change in Cash fell 12552.69% to -$21.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.8 million, marking a year-over-year increase of 3527.7%. This contributed to the annual value of -$6.1 million for FY2024, which is 9885.1% up from last year.
  • According to the latest figures from Q3 2025, Emergent BioSolutions' Change in Cash is -$21.8 million, which was down 12552.69% from $118.2 million recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Change in Cash registered a high of $401.6 million during Q4 2022, and its lowest value of -$344.2 million during Q2 2023.
  • In the last 5 years, Emergent BioSolutions' Change in Cash had a median value of -$32.7 million in 2024 and averaged -$19.6 million.
  • Per our database at Business Quant, Emergent BioSolutions' Change in Cash tumbled by 63649.64% in 2021 and then surged by 1077500.0% in 2024.
  • Emergent BioSolutions' Change in Cash (Quarter) stood at $172.3 million in 2021, then skyrocketed by 133.08% to $401.6 million in 2022, then tumbled by 94.05% to $23.9 million in 2023, then crashed by 312.55% to -$50.8 million in 2024, then skyrocketed by 57.09% to -$21.8 million in 2025.
  • Its last three reported values are -$21.8 million in Q3 2025, $118.2 million for Q2 2025, and $47.2 million during Q1 2025.